Who founded Nuvalent?

Nuvalent was founded by Matthew Shair, Henry Pelish, PhD in 2017.

Who are Nuvalent's investors?

Nuvalent's investors include Avoro Capital Advisors, Bain Capital Life Sciences, Viking Global, Wellington Management, Deerfield Management Company.

How much funding has Nuvalent raised?

Nuvalent has disclosed $135M raised across 1 of its 2 known rounds.

Where is Nuvalent headquartered?

Nuvalent is headquartered in Cambridge, US.

Nuvalent

Cambridge, US · Founded 2017 · Delaware corporation · 5 known investors

Find your way into Nuvalent

Paths you didn't know you had: your email and LinkedIn already hold routes to the Nuvalent team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Nuvalent is a biopharmaceutical company focused on structure-based drug discovery and the development of precision oncology therapies. Its team spans chemistry, biology, translational and clinical development, and commercial functions supporting cancer drug programs.

Biotech Healthtech Medical Devices

Founders & leadership

Nuvalent was founded in 2017 by Matthew Shair and Henry Pelish, PhD.

Matthew Shair Co-founderMatthew Shair is a professor of chemistry and chemical biology at Harvard University whose research focuses on therapeutics development and disease mechanisms. He founded Nuvalent, a biopharmaceutical company developing small-molecule kinase inhibitors for cancer.

Henry Pelish, PhDChief Scientific Officer

R. Porter JamesCEO

James Porter, PhDChief Executive Officer

Alex BalcomChief Financial Officer

Christopher Turner, MDChief Medical Officer

Benjamin Lane, PhDChief Technical Operations Officer

Deb Miller, MMSc, PhD, JDChief Legal Officer

Darlene Noci, ALMChief Development Officer

Georg Pirmin Meyer, MDChief International Officer

James PorterChief Executive Officer

Henry PelishChief Scientific Officer

Investors · 5

Avoro Capital Advisorslisted by Avoro Capital AdvisorsNew York

How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us

Bain Capital Life Scienceslisted by Bain Capital Life SciencesBoston

How we know: Bain Capital Life Sciences's portfolio page · board seat on SEC Form D · Not right? Tell us

Viking Globallisted by Viking GlobalStamford

How we know: Viking Global's portfolio page · Not right? Tell us

Wellington Managementlisted by Wellington ManagementBoston · $5M – $50M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Deerfield Management CompanyreportedNew York

How we know: a partner's Signal profile · Not right? Tell us

Funding

SEC filings, press & company announcements

$135M disclosed across 1 of 2 rounds · 2021

Undisclosed amountSeries AJan 2021
Source ↗

▶$135MraisedMay 2021 · 28 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Matthew ShairDirector
Andrew HackDirector
Cameron WheelerDirector
Gary GillilandDirector
Robert JacksonDirector
Joseph PearlbergDirector
R. Porter JamesExecutive Officer, Director
Alex BalcomExecutive Officer

Offering amount: $135M
Amount sold: $135M
First sale: Apr 2021
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

NuvectisNuvectis is a biopharmaceutical company developing oral small molecule therapies for cancer, including NXP900, an SRC Family Kinase inhibitor, and NXP800, a GCN2 activator being evaluated in solid tumors such as ovarian cancer and cholangiocarcinoma. Its drug candidates are in early-stage clinical trials for patients with advanced solid tumors.

RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

Companies working in the same space as Nuvalent.

Frequently asked questions

What does Nuvalent do?: Nuvalent is a biopharmaceutical company focused on structure-based drug discovery and the development of precision oncology therapies. Its team spans chemistry, biology, translational and clinical development, and commercial functions supporting cancer drug programs.
Who founded Nuvalent?: Nuvalent was founded by Matthew Shair, Henry Pelish, PhD in 2017.
Who are Nuvalent's investors?: Nuvalent's investors include Avoro Capital Advisors, Bain Capital Life Sciences, Viking Global, Wellington Management, Deerfield Management Company.
How much funding has Nuvalent raised?: Nuvalent has disclosed $135M raised across 1 of its 2 known rounds.
Where is Nuvalent headquartered?: Nuvalent is headquartered in Cambridge, US.